Drew Therapeutics Rebrands to Fight Opioid Crisis
News related to:AI Financial Corporation · 2 min read
LAS VEGAS, October 14, 2026 /CourierPR/ -- AI Financial Corporation has rebranded its biotech business as Drew Therapeutics in honor of Andrew Witkoff, who succumbed to opioid addiction in 2011 at the young age of 22. The rebranding of the biotech company marks a significant step in the company's commitment to developing non-addictive treatments for pain, following the loss of Andrew Witkoff, the brother of AI Financial's Chairman, Zach Witkoff.
The new name, Drew Therapeutics Corporation, is intended to serve as a tribute to Andrew Witkoff and to reinforce the company's ongoing research into non-addicting painkillers. AI Financial, a leading fintech specializing in agentic commerce, has a robust pipeline of non-addictive treatments for pain, and the biotech segment will now operate as a separate, independent public company, as previously announced.
The CEO's statement underscores the company's dedication to addressing the severe opioid crisis, which has claimed more than 700,000 lives in the United States over the past decade, more than all military casualties in the last 100 years in all wars and conflicts combined.
The opioid crisis has not only claimed lives but also contributed to a decline in overall American life expectancy, which rarely falls in the absence of major wars or pandemics.
The company's new tagline, "From Pain Comes Purpose," was inspired by those who respond to opioid-related tragedy by supporting greater awareness of the opioid epidemic, personal outreach to families that suffer from addiction, and investing in the science of non-addicting treatments for pain.
Drew Therapeutics Corporation, led by Dr. Amol Soin, a renowned leader in pain management research and applications, is currently developing and marketing its lead investigational program, an innovative, proprietary formulation of low-dose naltrexone (LDN) for Complex Regional Pain Syndrome (CRPS), which has received FDA orphan drug designation and is advancing through clinical development. Drew is also developing the Drew Clear Patch, a topical pain-relief technology designed for targeted, non-invasive treatment.
AI Financial's biotech segment, formerly known as Alyea Therapeutics Corporation, will be rebranded to Drew Therapeutics Corporation. Dr. Soin earned awards and patents for his innovative ideas, including the invention of Biphasic release of Low-Dose Naltrexone (LDN) and the "Clear Patch," a topical application technology both designed to treat pain without the opioids effect.
The rebranding of Drew Therapeutics Corporation is the first of a series of pending announcements.
AI Financial Corporation, a leading fintech specializing in agentic commerce, is dedicated to developing intelligent financial products and infrastructure for the emerging intelligence economy, spanning intelligent-card issuance, programmable finance, tokenization, treasury-enabled utility, Vault-based identity and permissions, and secure AI-to-AI transactions.